136916-19-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Fluoro-6-nitrophenylacetic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Organic Chemistry Reactions:
As a reagent, 2-Fluoro-6-nitrophenylacetic acid is employed in a range of organic chemistry reactions, facilitating the formation of complex organic molecules and contributing to the advancement of organic synthesis techniques.
Used in Medicinal Chemistry Research:
2-Fluoro-6-nitrophenylacetic acid serves as a valuable research tool in medicinal chemistry, aiding scientists in understanding the structure-activity relationships of drug molecules and guiding the design of novel therapeutic agents.
Used in Drug Discovery and Development:
The chemical properties of 2-Fluoro-6-nitrophenylacetic acid make it an important molecule for drug discovery and development, enabling the creation of innovative pharmaceuticals with potential applications in various therapeutic areas.

Upstream product

• 6921-22-8 1,2-difluoro-3-nitrobenzene 
• 872141-24-7 2-(3-fluoro-2-nitrophenyl)malonic acid dimethyl ester 
• 866209-62-3 2-(2-fluoro-6-nitrophenyl)malonic acid dimethyl ester 

Downstream Products

• 71294-03-6 7-fluoro-1,3-dihydro-indol-2-one 
• 887587-80-6 C₈H₈FNO₂ 
• 1357192-61-0 methyl 1-(2-fluoro-6-nitrophenyl)cyclobutanecarboxylate 
• 1357192-60-9 4′-fluoro-5′-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-1'-methylspiro[cyclobutane-1,3'-indol]-2'(1'H)-one 
• 138343-94-9 4-fluoro-1,3-dihydro-2H-indol-2-one 

Relevant academic research and scientific papers

Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor

Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER) = 6.

DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)- 1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348)

We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: [image] or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

Substituted propylamine derivatives and methods of their use

The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Progesterone receptor antagonists, contraceptive regimens, and kits

A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.